120 related articles for article (PubMed ID: 15093570)
1. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas.
Anninga JK; van de Vijver MJ; Cleton-Jansen AM; Kristel PM; Taminiau AH; Nooij M; Egeler RM; Hogendoorn PC
Eur J Cancer; 2004 May; 40(7):963-70. PubMed ID: 15093570
[TBL] [Abstract][Full Text] [Related]
2. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study.
Somers GR; Ho M; Zielenska M; Squire JA; Thorner PS
Pediatr Dev Pathol; 2005; 8(5):525-32. PubMed ID: 16211448
[TBL] [Abstract][Full Text] [Related]
3. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma.
Thomas DG; Giordano TJ; Sanders D; Biermann JS; Baker L
Clin Cancer Res; 2002 Mar; 8(3):788-93. PubMed ID: 11895910
[TBL] [Abstract][Full Text] [Related]
4. Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.
Cuadros M; Talavera P; López FJ; García-Peréz I; Blanco A; Concha A
Pathobiology; 2010; 77(1):38-45. PubMed ID: 20185966
[TBL] [Abstract][Full Text] [Related]
5. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
6. Quantitative assessment of HER2/neu expression by real-time PCR and fluorescent in situ hybridization analysis in low-grade osteosarcoma.
Lee WI; Bacchni P; Bertoni F; Maeng YH; Park YK
Oncol Rep; 2004 Jul; 12(1):125-8. PubMed ID: 15201972
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD
Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051
[TBL] [Abstract][Full Text] [Related]
8. Integrated assessment of potential value of erbB-2 amplification or expression status as novel therapy target in Chinese children and adolescents with osteosarcoma.
Shang J; Bi ZG; Ji HF; Wang WB
Chin Med J (Engl); 2009 Jul; 122(13):1521-4. PubMed ID: 19719941
[TBL] [Abstract][Full Text] [Related]
9. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
[TBL] [Abstract][Full Text] [Related]
10. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry.
Pellegrini C; Falleni M; Marchetti A; Cassani B; Miozzo M; Buttitta F; Roncalli M; Coggi G; Bosari S
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3645-52. PubMed ID: 14506153
[TBL] [Abstract][Full Text] [Related]
11. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
Yano T; Doi T; Ohtsu A; Boku N; Hashizume K; Nakanishi M; Ochiai A
Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
[TBL] [Abstract][Full Text] [Related]
12. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
13. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C
Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
[TBL] [Abstract][Full Text] [Related]
14. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
15. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
[TBL] [Abstract][Full Text] [Related]
16. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
17. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma.
Baumhoer D; Smida J; Specht K; Bink K; Quintanilla-Martinez L; Rosemann M; Siggelkow H; Nathrath WB; Atkinson MJ; Bielack S; Jundt G; Nathrath M
Hum Pathol; 2011 Jun; 42(6):859-66. PubMed ID: 21292304
[TBL] [Abstract][Full Text] [Related]
19. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
[TBL] [Abstract][Full Text] [Related]
20. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas.
Park HR; Min K; Kim HS; Jung WW; Park YK
Pathol Res Pract; 2008; 204(8):575-82. PubMed ID: 18440723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
